A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease:

Extensive atherosclerotic plaque burden in the lower extremities often leads to symptomatic peripheral artery disease (PAD) including impaired walking performance and claudication. Interleukin-1β (...